Ligand Pharmaceuticals (LGND) Short Interest Ratio & Short Volume

Short interest is the volume of Ligand Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 826,600 shares of LGND short. 4.98% of Ligand Pharmaceuticals' shares are currently sold short. Learn More on Ligand Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LGND shares currently have a short interest ratio of 5.0. Learn More on Ligand Pharmaceuticals's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ligand Pharmaceuticals: Simplex Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.98% of Ligand Pharmaceuticals' floating shares are currently sold short.

Ligand Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 826,600 shares, an increase of 23.0% from the previous total of 672,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Ligand Pharmaceuticals currently has issued a total of 17,705,000 shares. Some of Ligand Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Ligand Pharmaceuticals currently has a public float of 16,600,000 shares.

4.98% of Ligand Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Ligand Pharmaceuticals: Ironwood Pharmaceuticals, Inc. (13.96%), MannKind Co. (13.21%), Innoviva, Inc. (18.46%), Dynavax Technologies Co. (14.17%), OPKO Health, Inc. (23.81%), Arcturus Therapeutics Holdings Inc. (18.77%), Nurix Therapeutics, Inc. (14.32%), Praxis Precision Medicines, Inc. (4.69%), Geron Co. (9.04%), COMPASS Pathways plc (5.39%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks.

Short selling LGND is an investing strategy that aims to generate trading profit from Ligand Pharmaceuticals as its price is falling. LGND shares are trading up $0.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Ligand Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LGND, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LGND, twice per month. The most recent reporting period available is April, 15 2024.